We collected information about Juventas Therapeutics Inc Hours for you. Follow the liks to find out everything about Juventas Therapeutics Inc Hours.
http://juventasinc.com/news/2016/juventas_Feb3.html
Juventas Therapeutics is a clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our primary focus is the treatment of non-healing wounds in patients with advanced peripheral artery disease (PAD). Our product candidate, JVS-100, is a non-viral gene therapy that ...
https://www.dnb.com/business-directory/company-profiles.juventas_therapeutics_inc.06834d517e34ebb2103b72040a9bde95.html
Company Description: Juventas Therapeutics, Inc. is located in Cleveland, OH, United States and is part of the Scientific Research and Development Services Industry. Juventas Therapeutics, Inc. has 5 total employees across all of its locations and generates $576,744 in sales (USD). (Sales figure is modelled).
https://www.linkedin.com/company/juventas-therapeutics-inc-
Juventas Therapeutics, Inc. | 418 followers on LinkedIn. Juventas Therapeutics is a private, clinical stage biotechnology company developing novel …
https://www.bloomberg.com/profile/company/0563120D:US
Company profile page for Juventas Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information
http://juventasinc.com/news/2015/juventas_May26.html
CLEVELAND and SEVILLE, Spain, May 26, 2015 /PRNewswire/ -- Juventas Therapeutics, Inc., a clinical-stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases, today presented new 12-month data demonstrating that a single administration of Juventas' non-viral DNA plasmid gene therapy, JVS ...
https://pitchbook.com/profiles/company/42952-87
Juventas Therapeutics General Information Description. Developer of regenerative therapies intended to treat cardiovascular diseases and ischemic disorders. The company's therapies include non-viral gene therapy which can activate natural processes to repair the body, enabling patients to begin treatment promptly and result in a likelihood of successful treatment.
https://www.clinicaltrials.gov/ct2/show/NCT01643590
Juventas Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT01643590 Other Study ID Numbers: JTCS-004 : First Posted: July 18, 2012 Key Record Dates: Last Update Posted: February 7, 2014 Last Verified: February 2014
https://casipharmaceuticals.com/investor-relations/news/casi-pharmaceuticals-announces-partner-juventas-completes-65-million
ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the equivalent of $65 million financing and has initiated and enrolled the first ...
https://healthcare.utah.edu/clinicaltrials/trial.php?id=FP00004335
Juventas Therapeutics, Inc. JVS-100 for the Treatment of Ischemic Heart Failure IND #14203 Signs of acute heart failure within 24 hours of scheduled infusion History of aortic valve regurgitation classified as “moderate-severe” or worse Patients will be excluded who have: o Known prior trauma to the coronary sinus o In dwelling instrumentation that may hamper …
Searching for Juventas Therapeutics Inc Hours?
You can just click the links above. The info is collected for you.
